论文部分内容阅读
目的分析非小细胞肺癌患者化疗诱发的Ⅳ度粒细胞减少的相关因素,为合理使用人粒细胞集落刺激因子提供依据。方法收集化疗诱发的Ⅳ度粒细胞减少的非小细胞肺癌患者的临床资料(A组),以同期化疗未出现粒细胞减少的非小细胞肺癌患者作为对照组(B组),采用单因素和多因素分析其危险因素。结果单因素分析显示,非小细胞肺癌患者出现Ⅳ度粒细胞减少的相关因素为PS2分、临床分期Ⅳ期、化疗前1周内使用GCSF、化疗延期大于1周、化疗周期数≥4个、多西紫杉醇+顺铂方案、合并放射治疗。多因素分析显示,出现Ⅳ度粒细胞减少的相关因素为临床分期Ⅳ期、化疗前1周内使用GCSF、化疗延期大于1周、化疗周期数≥4个、多西紫杉醇+顺铂方案。结论Ⅳ度粒细胞减少的危险因素为临床分期Ⅳ期、化疗前1周内使用GCSF、化疗延期大于1周、化疗周期数≥4个、多西紫杉醇+顺铂方案。高风险患者应该预防性应用GCSF。
Objective To analyze the factors associated with chemotherapy-induced IV granulocytopenia in non-small cell lung cancer (NSCLC) patients and provide evidence for the rational use of human granulocyte colony-stimulating factor. Methods The clinical data of patients with non-small cell lung cancer induced by chemotherapy-induced IV granulocytopenia were collected (group A), and patients with non-small cell lung cancer without neutropenia treated with chemotherapy were used as control group (group B). Univariate and Multivariate analysis of risk factors. RESULTS Univariate analysis showed that the relevant factors for the IV degree neutropenia in patients with non-small cell lung cancer were PS2 score, clinical stage IV, GCSF within 1 week before chemotherapy, chemotherapy delay was more than 1 week, and the number of chemotherapy cycles was ≥4. Docetaxel + cisplatin regimen, combined with radiation therapy. Multivariate analysis showed that the relevant factors for IV granulocytopenia were clinical stage IV, use of GCSF within 1 week prior to chemotherapy, chemotherapy delay of more than 1 week, number of chemotherapy cycles ≥ 4, docetaxel + cisplatin regimen. Conclusion The risk factors for IV granulocytopenia are clinical stage IV, chemotherapy use one week before chemotherapy, chemotherapy delayed for more than 1 week, chemotherapy cycles ≥4, docetaxel + cisplatin regimen. High-risk patients should use GCSF prophylactically.